Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

M Ruella; S S Kenderian; O Shestova; M Klichinsky; J J Melenhorst; M A Wasik; S F Lacey; C H June; S Gill

doi:10.1038/leu.2016.262

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28.

Authors

M Ruella^{1

2

3}, S S Kenderian^{1

2

3

4}, O Shestova^{1

2

3}, M Klichinsky^{1

2

5}, J J Melenhorst^{1

2

3}, M A Wasik^{2

3}, S F Lacey^{1

2

3}, C H June^{1

2

3

6}, S Gill^{1

2

4

7}

Affiliations

¹ Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
² Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
³ Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
⁴ Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
⁵ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA.
⁷ Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

PMID: 27677739
DOI: 10.1038/leu.2016.262

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Animals
Antibodies
Antigens, CD19 / immunology*
Cytokines / drug effects*
Cytokines / metabolism
Heterografts
Humans
Lymphoma, B-Cell / immunology
Mice
Piperidines
Protein Kinase Inhibitors / therapeutic use
Pyrazoles / pharmacology
Pyrazoles / therapeutic use*
Pyrimidines / pharmacology
Pyrimidines / therapeutic use*
Receptors, Antigen, T-Cell / immunology*
Recombinant Fusion Proteins / immunology
Syndrome

Substances

Antibodies
Antigens, CD19
Cytokines
Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
Receptors, Antigen, T-Cell
Recombinant Fusion Proteins
ibrutinib
Adenine

Publication types

MeSH terms

Substances

Grants and funding